BMYMP

BRISTOL MYERS SQUIBB CO

NYSE · Pharmaceutical Preparations · Inc. DE · CIK 0000014272
Vol
Exchange NYSE·Sector Pharmaceutical Preparations·Inc. DE·CIK 0000014272

Recent Activity

Aug 17, 2026 fda_pdufa
PDUFA: BMYMP — iberdomide in relapsed or refractory multiple myeloma — 2026-08-17
FDA target action date 2026-08-17 for BMYMP (BRISTOL MYERS SQUIBB CO). Drug: iberdomide. Indication:

Analyst Ratings

Historical distribution39% buy · 36 analysts · no recent coverage
6Strong Buy
8Buy
20Hold
2Sell
0Strong Sell

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution: 39% buy across 36 analysts — 6 strong buy, 8 buy, 20 hold, 2 sell, 0 strong sell. No current recommendation available.

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202668202039%
May 1, 202669192042%
Apr 1, 202669192042%
Mar 1, 202669192042%
Feb 1, 202668182041%
Jan 1, 202667192038%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Aug 17, 2026
fda_pdufa
PDUFA: BMYMP — iberdomide in relapsed or refractory multiple myeloma — 2026-08-17
FDA target action date 2026-08-17 for BMYMP (BRISTOL MYERS SQUIBB CO). Drug: iberdomide. Indication: relapsed or refractory multiple myeloma. FDA acce